Platelet Rich Plasma VS Platelet Fibrin Plasma in Treatment of Diabetes Related Wound：a Randomized Controlled Trial

NCT ID: NCT05979584

Last Updated: 2025-03-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 57 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-20
• Study Completion Date: 2025-03-09

Brief Summary

The goal of this randomized control trial is to compare the efficacy and safety of Platelet Rich Plasma VS Platelet Fibrin Plasma in patients with diabetes foot ulcer. The main question it aims to answer are:

• Whether the Platelet Fibrin Plasma have noninferior efficacy than Platelet Rich Plasma in treatment of diabetes foot ulcer？
• Whether the Platelet Fibrin Plasma have noninferior safety than Platelet Rich Plasma in treatment of diabetes foot ulcer？ Participants will be assigned with a 1:1 ratio into intervention group and control group.

Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure. Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.

Conditions

Diabetic Foot

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Platelet Fibrin Plasma

Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.

Group Type: EXPERIMENTAL

Platelet Fibrin Plasma

Intervention Type: DEVICE

Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.

Platelet Rich Plasma

Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.

Group Type: PLACEBO_COMPARATOR

Platelet Rich Plasma

Intervention Type: DEVICE

Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.

Interventions

Platelet Fibrin Plasma

Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.

Intervention Type: DEVICE

Platelet Rich Plasma

Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. The patient is aged 18-80 years old;

2. Diagnosed as type 1 or type 2 diabetes according to the World Health Organization standard, blood sugar has been controlled before enrollment, and the level of Glycated hemoglobin HbA1c is less than 10%;

3. diabetes wounds with poor healing or prolonged healing need standard wound treatment;

4. There is no disseminated infection or the disseminated infection has been controlled;

5. After preparing the wound bed, the condition for using platelet plasma to close the wound is met;

6. Voluntarily sign an informed consent form;

Exclusion Criteria

1. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;

2. Severe ischemia of the wound surface, unable to seek medical attention or not yet corrected;

3. Uncontrolled systemic or disseminated infections;

4. Blood glucose is out of control or not yet effectively controlled;

5. Blood system diseases with uncorrected coagulation dysfunction or platelet dysfunction;

6. There is active bleeding inside the wound, and routine basic treatment plans cannot be implemented;

7. Platelets ≤ 80 × 10^9, hemoglobin<90g/L;

8. Patients with advanced malignant tumors;

9. Active period of autoimmune diseases;

10. The patient is unable to cooperate or has mental disorders;

11. According to the judgment of the researchers, the patient has a clear and irremovable cause that affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University Third Hospital

OTHER

Sponsor Role: lead

Responsible Party

Long Zhang

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Peking University 3rd Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

Long2023-DFU-PFP

Identifier Type: -

Identifier Source: org_study_id